# Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

> **NCT02032173** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Macular Edema
- Macular Degeneration
- Diabetes

## Interventions

- **DRUG:** Ranibizumab 0.5mg

## Key facts

- **NCT ID:** NCT02032173
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-19
- **Primary completion:** 2015-04-29
- **Final completion:** 2015-04-29
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Study was prematurely discontinued as it was unethical to continue based on a change in ranibizumab (RFB) marketing authorization.
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032173, "Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02032173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*